UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D/A
Under the Securities Exchange Act of 1934
(Amendment No. 3)
PHARMA-BIO SERV, INC.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
71711N100
(CUSIP Number)
Olga Filippova
730 FIFTH AVENUE, 25TH FLOOR
NEW YORK, NY 10019
212-359-0200
(Name, Address and Telephone Number of Person Authorized to Receive Notices
and Communications)
December 29, 2009
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition that is the subject of this Schedule 13D, and
is filing this schedule because of 240.13d1(e), 240.13d-1(f) or 240.13d-
1(g), check the following box. [ ] Note: Schedules filed in paper format
shall include a signed original and five copies of the schedule,
including all exhibits. See 240.13d-7 for other parties to whom copies are
to be sent.
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall
not be deemed to be "filed" for the purpose of Section 18 of the
Securities Exchange Act of 1934 ("Act") or otherwise subject to the
liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
CUSIP 71711N100
13D/A
1 Name of Reporting Person
Barron Partners LP
I.R.S. Identification No. of Above Person
431981699
2 Check the Appropriate Box if a Member of a Group (a) [ ]
(b) [ x ]
3 SEC Use Only
4 Source of Funds
WC
5 Check Box if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e)
[ ]
6 Citizenship or Place of Organization
Delaware
Number of 7 Sole Voting Power
Shares
Owned 30,000 shares
By Each 8 Shared Voting Power
Reporting 0
Person With
9 Sole Dispositive Power
30,000 shares
10 Shared Dispositive Power
0
11 Aggregate Amount Beneficially Owned by Each Reporting Person
30,000
12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
[ ]
13 Percent of Class Represented by Amount in Row (11)
0.1%
14 Type of Reporting Person
PN
Item 1. Security and Issuer.
This statement relates to shares of common stock, par value $0.0001 per
share, (the "Common Stock") of Pharma-Bio Serv, Inc. a Delaware corporation
(the "Company") having its principal executive offices at Pharma-Bio Serv
Building, Industrial Zone Lot 14, Barrio Higuillar, Dorado, Puerto Rico
00646.
Item 2. Identity and Background.
This Statement is filed by Barron Partners LP, a Delaware Limited
Partnership (the "Reporting Person"), whose business address is 730 Fifth
Avenue, 25th Floor, New York, NY 10019. The Reporting Person is
principally engaged in making investments.
The General Partner of the Reporting Person is Barron Capital Advisors LLC,
a Delaware Limited Liability Company, (the "General Partner"). Andrew
Barron Worden is the managing member of the General Partner.
During the last five years, to the best knowledge of the Reporting Person,
neither the Reporting Person nor any controlling person of the Reporting
Person has (i) been convicted in a criminal proceeding, or (ii) been a
party to a civil proceeding of a judicial or administrative body of
competent jurisdiction and as a result of such proceeding was or is subject
to a judgment, decree or final order enjoining future violations of, or
prohibiting or mandating activities subject to, Federal or State securities
laws or finding any violation with respect to such laws.
Item 3. Source and Amount of Funds or Other Consideration.
N/A
Item 4. Purpose of Transaction.
N/A
Item 5. Interest in Securities of the Issuer.
(c) On December 8, 2009 the Reporting Person sold 15,000 shares of Common
Stock at a price of $0.30 per share in an open market transaction. On
December 29, 2009 the Reporting Person sold 2,482,574 shares of Common
Stock, warrants to purchase 680,800 shares of the Issuer's common stock at
a price of $1.10 per share and warrants to purchase 680,800 shares of the
Issuer's common stock at a price of $1.65 per share for a total
consideration of $496,515 in a private transaction.
(e) On December 29, 2009 the Reporting Person ceased to be the beneficial
owner of more than five percent of the class of securities.
Item 6. Contracts, Arrangements, Understandings or
Relationships with Respect to Securities of the Issuer.
Not applicable.
Item 7. Material to be Filed as Exhibits.
Not applicable.
SIGNATURE1
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
Date: January 12, 2010
/s/ ANDREW BARRON WORDEN
--------------------
Signature
Andrew Worden, Managing Member of the General Partner of Barron Partners LP